Synthetic biology and precision medicine in blood and gynaecological cancers
Prof Mohamed Desouki speaks to ecancer about his talks on the diagnostic criteria of serous tubal intraepithelial carcinoma at the BGICC 2023.
There is compelling evidence that serous tubal intraepithelial carcinoma is a precursor of high-grade serous ovarian carcinoma. Prof Desouki summarises the updates in the diagnostic criteria of the series.
He also discusses his other talk which looks at the morphological criteria for diagnosing sex cord-stromal tumours.
My other two talks about the GYN pathology, one of them will talk about the precursor lesion for the high-grade serous carcinoma of the ovary. Now there is a lot of literature about the precursor lesion of this high-grade tumour of the ovary which arises from the fallopian tube. This lesion is called serous tubal intraepithelial carcinoma, the diagnosis of which is maybe a little bit challenging and there is a lot of inconsistency in the diagnosis. So this talk will try to summarise the updates in the diagnostic criteria of the serous tubal intraepithelial carcinoma.
The second talk will talk about one of the rare types of ovarian cancer which is sex cord-stromal tumour. This usually affects the younger age group, maybe in their 20s or even less in age. So the talk will be about the morphologic criteria of diagnosing sex cord-stromal tumours.
Synthetic biology and precision medicine in blood and gynaecological cancers
Adagrasib shows durable clinical benefit in advanced KRAS-mutant NSCLC
OncoAlert Round Up for September 15-21, 2023
The Southeast Asian Breast Cancer Symposium; background, aims and successes
TARGeted IORT INTRABEAM is a useful treatment option for early stage breast cancer
TARGIT-E: Intraoperative Radiotherapy (IORT) in elderly patients with small breast cancer
The use of IORT at Universitätsmedizin Mannheim hospital
Tusamitamab ravtansine combined with SoC shows encouraging anti-tumour activity for patients with nonsquamous NSCLC
Initial results from a phase 1 dose escalation trial of E-602 shows efficacy in solid tumours